Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Pemetrexed (ALIMTA) is novel multitargeted antineoplastic agent
September 8th, 2004
Pemetrexed (ALIMTA) is a novel multitargeted antineoplastic agent. "Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribornucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric, and pancreatic cancer," a scientist writing in the journal Clinical Cancer Research reports. "In non-small cell lung cancer, single-agent...
Source: Vaccine Weekly (2004-09-08)
|
